Compare OGI & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGI | CMPX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.3M | 927.5M |
| IPO Year | 2015 | 2020 |
| Metric | OGI | CMPX |
|---|---|---|
| Price | $1.36 | $5.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.43 |
| AVG Volume (30 Days) | 517.9K | ★ 1.8M |
| Earning Date | 05-11-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.10 | N/A |
| Revenue Next Year | $13.92 | $677.91 |
| P/E Ratio | $13.91 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.85 | $1.33 |
| 52 Week High | $2.24 | $6.88 |
| Indicator | OGI | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 41.01 | 43.75 |
| Support Level | $1.29 | $4.86 |
| Resistance Level | $1.42 | $5.86 |
| Average True Range (ATR) | 0.05 | 0.29 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 17.04 | 46.00 |
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.